XBiotech Inc. (XBIT) Stock Price & Analysis
XBiotech Inc. (XBIT) closed at USD 2.16 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.16; the Oct 15, 2026 session ranged USD 2.13–2.26 on volume of 85,020 shares. Market capitalization is $65.85M, with a 52-week range of USD 2.09–3.44 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/XBIT.md
Key facts (XBIT)
- Analysts: None.
- Total return with dividends: 1Y -13.3% vs S&P 500 +18.1%; 5Y -83.7% vs S&P 500 +85.1%.
Analysts (XBIT)
Consensus None.
Total return (dividends reinvested) (XBIT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -13.3% | -83.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -13.3% | -30.3% |
| Volatility (annualized) | 43.8% | 60.2% |
| Max drawdown | -26.9% (Nov 2025→Sep 2026) | -86.4% (Nov 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 2.16 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.16 |
| Open | USD 2.16 |
| Day Range | USD 2.13 – 2.26 |
| 52-Week Range | USD 2.09 – 3.44 |
| Volume | 85,020 shares |
| Market Cap | $65.85M |
| Exchange | NMS |
Technical Analysis (XBIT)
Nexqual's technical model rates XBIT "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.44 (neutral) |
| vs SMA50 | Below (USD 2.23) |
| MACD | -0.01 (negative) |
Analyst Ratings (XBIT)
Wall Street analysts rate XBIT "None", per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | None |
|---|
Earnings (XBIT)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2020-03-31 | USD 0 vs est 0.06 ▼ miss |
| 2019-12-31 | USD -0.28 vs est -0.15 ▼ miss |
| 2019-09-30 | USD -0.15 vs est -0.15 ▲ beat |
| 2019-06-30 | USD -0.16 vs est -0.15 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (XBIT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -29.94% |
| Current Ratio | 33.15 |
| Total Cash | $109.53M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (XBIT)
Nexqual rates XBiotech Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $110M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$41M (TTM) |
| Efficiency | Critical — ROE -30%, ROA -19.3% |
Ownership (XBIT)
| Insider Ownership | +36.87% |
|---|---|
| Institutional Ownership | +6.73% |
| Shares Outstanding | 30.49M |
| Float | 22.84M |
| Short % of Float | +1.26% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (XBIT)
XBiotech Inc. is led by Sushma Shivaswamy (age 47), Interim CEO & Chief Scientific Officer, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Interim CEO & Chief Scientific Officer | Sushma Shivaswamy (age 47) |
|---|---|
| Founder & Chairman | John Simard (age 63) |
| Director of Finance | Angela Hu (age 41) |
| Senior Vice President of Clinical Operations & Analytical Quality | Qian Wu |
Major Backers & Investors (XBIT)
Notable institutional backers of XBiotech Inc. include RBF Capital, LLC, Fidelity, Morgan Stanley, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RBF Capital, LLC | 0.65% |
| Fidelity | 0.57% |
| Morgan Stanley | 0.49% |
| Bridgeway Capital Management, LLC | 0.32% |
| Millennium Management | 0.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.62% |
| BlackRock | 1.31% |
| Geode Capital | 0.7% |
| State Street | 0.24% |
| Northern Trust | 0.22% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt